Journal of Ophthalmic Inflammation and Infection, 2019 Background A retrospective observational clinical study to evaluate the safety and effectiveness of the injectable 0.19-mg fluocinolone acetonide intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema.
Lea F. Weber +6 more
doaj +1 more source
An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy [PDF]
, 2016 AIM: To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Thirty-two DME patients were enrolled.
Carnovale, Anna +7 more
core +1 more source
International Medical Case Reports Journal, 2021 João Heitor Marques,1 Ana Carolina Abreu,1 Nisa Silva,1 Angelina Meireles,1,2 Bernardete Pessoa,1,2 João Melo Beirão1,2 1Serviço de Oftalmologia, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Instituto ...
Marques JH +5 more
doaj
Comparison between “early” or “late” intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six months follow-up [PDF]
, 2017 AIM: The aim of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-months follow-up.
AUTOLITANO, MONICA +6 more
core +1 more source
Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation [PDF]
, 2022 The long-term effect of intravitreal Fluocinolone acetonide (FAc) on retinal morphology and function in diabetic macular edema (DME) was investigated. Seventeen eyes of twelve consecutive DME patients, treated by intravitreal FAc, were retrospectively ...
Falsini, Benedetto (ORCID:0000-0002-3569-4968) +4 more
core +1 more source
Therapeutic Advances in Ophthalmology, 2019 Introduction: Macular edema after central retinal vein occlusion is a common cause of vision loss. Upregulation of vascular endothelial growth factor and higher levels of inflammatory mediators have been involved in the pathogeny of the macular edema in ...
João Coelho +2 more
doaj +1 more source
Sustained-release steroids for the treatment of diabetic macular edema. [PDF]
, 2015 Glucocorticoids have been used for decades in the treatment of ocular disorders via topical, periocular, and more recently intravitreal routes. However, their exact mechanisms of action on ocular tissues remain imperfectly understood.
Behar-Cohen, F., Daruich, A., Matet, A.
core +1 more source
Treatment Strategies for Refractory Diabetic Macular Edema: Switching Anti-VEGF Treatments, adopting corticosteroid-based treatments, and combination therapy [PDF]
, 2016 Introduction: The pathophysiology of diabetic macular edema (DME) is complex, involving vascular endothelial growth factor (VEGF) and other inflammatory mediators.
Ciulla, Thomas A., Hussain, Rehan M.
core +1 more source
Micro-implant d'acétonide de fluocinolone (ILUVIEN(®)) pour l'oedème maculaire diabétique chronique [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema]. [PDF]
, 2015 Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular ...
Behar-Cohen, F., Soubrane, G.
core +1 more source
Incidence and treatment approach of intraocular pressure elevation after various types of local steroids for retinal diseases [PDF]
, 2023 Purpose For the treatment of macular edema, in addition to the use of antivascular endothelial growth factors, steroids are also used intravitreally and sub-Tenon.
Abdin, Alaa Din +4 more
core +1 more source